Table 1 Characteristics of the patients from which samples have been used in this study. nd not determined, PSA prostate-specific antigen
Patients | Age | Gleason score | PSA (ng/mL) | Clinical tumoral size: cT | Pathological tumoral size: pT | Metastatic risk |
|---|---|---|---|---|---|---|
1 | 65 | 6 (3 + 3) | 3.7 | 1 | 2c | Low risk |
2 | 57 | 6 (3 + 3) | 4.38 | 1 | 2 | |
3 | 51 | 6 (3 + 3) | 3.7 | 2 | 2 | |
4 | 49 | 6 (3 + 3) | 4.52 | 2 | 2c | |
5 | 56 | 6 (3 + 3) | 4.4 | 2 | 2c | |
6 | 63 | 7 (3 + 4) | 10 | 1 | 2c | Intermediate risk |
7 | 66 | 7 (3 + 4) | 10 | 2 | 2c | |
8 | 59 | 7 (3 + 4) | 13 | 2 | 2b | |
9 | 67 | 7 (3 + 4) | 12.5 | 1 | 3a | |
10 | 67 | 7 (3 + 4) | 14 | 1 | 3a | |
11 | 66 | 7 (3 + 4) | 10.4 | 0 | 3a | |
12 | 55 | 7 (3 + 4) | 13 | 1 | 3a | |
13 | 56 | 9 (4 + 5) | 26 | 3 | 3a | High risk |
14 | 63 | 7 (4 + 3) | 25.6 | 3 | 3b | |
15 | 70 | 9 (4 + 5) | 24.5 | 2 | 3b | |
16 | 59 | 8 (4 + 4) | 14 | 2 | 4 | |
17 | 48 | 7 (4 + 3) | 14.28 | 2 | 3b | |
18 | 66 | 7 (4 + 3) | 44 | 2 | 3a | |
19 | 53 | 7 (4 + 3) | 20 | 2 | 3a | |
20 | 63 | 7 (4 + 3) | 28 | 2 | nd |